Liraglutide and SSRIs (Sertraline, Escitalopram): Drug Interaction Guide

Print or save as PDF

Is there a known interaction between liraglutide and SSRIs?

Neither the Saxenda nor the Victoza label identifies an interaction with sertraline or escitalopram [1][2]. The Saxenda label's drug interactions section covers one topic: delayed gastric emptying and oral medicines [1]. The Victoza label adds a second: low blood sugar when liraglutide is used with insulin or an insulin secretagogue such as a sulfonylurea [2]. Neither section mentions SSRIs, sertraline or escitalopram.

The Zoloft label's interaction table lists MAOIs, pimozide, other serotonergic drugs, drugs that interfere with hemostasis, highly protein-bound drugs, CYP2D6 substrates, phenytoin and QTc-prolonging drugs; liraglutide is not among them [3].

What the liraglutide label says about oral medicines

Liraglutide slows gastric emptying, so the Saxenda label flags the potential to affect absorption of anything taken by mouth and says to monitor for consequences of delayed absorption [1]. The same label then reports what the clinical pharmacology trials found: liraglutide did not affect the absorption of the tested oral medicines to a clinically relevant degree [1]. The Victoza label says the same and advises caution with oral medicines [2].

The clearest numbers come from the oral contraceptive study in the Saxenda label. With 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel, liraglutide lowered ethinylestradiol peak concentration by 12% and levonorgestrel peak concentration by 13%, left ethinylestradiol AUC unchanged, raised levonorgestrel AUC by 18%, and delayed time to peak by about 1.5 hours [1].

Liraglutide is broken down like a large protein, without a specific organ of elimination, has a plasma half-life of about 13 hours, and intact drug is not found in urine or feces [1].

Serotonin syndrome and the Zoloft label

The Zoloft label warns that serotonin syndrome can occur with ZOLOFT alone, and that risk rises with triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, St John's wort and MAOIs [3]. Liraglutide is not on that list, and the GLP-1 receptor agonist class does not appear in it.

The label's description of serotonin syndrome includes mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular signs (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures and gastrointestinal symptoms [3]. The label says to discontinue ZOLOFT and any serotonergic agents immediately if these symptoms occur and to start supportive treatment [3].

Blood sugar and the hypoglycemia warning

The Saxenda hypoglycemia warning is about insulin and insulin secretagogues, not antidepressants. Among adults with type 2 diabetes taking a sulfonylurea, blood glucose below 54 mg/dL with or without symptoms occurred in 28.2% on Saxenda versus 12.7% on placebo, in a trial where sulfonylurea doses were halved at the start [1]. The Victoza label says to consider reducing the dose of a sulfonylurea or insulin when liraglutide is started [2].

Mood and suicidal thoughts on both drugs

Every SSRI carries the antidepressant boxed warning for suicidal thoughts and behaviors; the Zoloft label's pooled figures show, per 1,000 patients treated, 14 more cases under age 18, 5 more at ages 18 to 24, 1 fewer at 25 to 64, and 6 fewer at 65 and over [3].

For liraglutide, FDA said on 2026-01-13 that after reviewing a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials (107,910 patients) plus a claims cohort of 2,243,138 new users, it found no increased risk of suicidal ideation or behavior, and asked the makers of Saxenda, Wegovy and Zepbound to remove that warning [6]. The Saxenda label effective 2026-02-25 no longer contains a suicidal behavior and ideation section [1], and the Victoza label never mentioned one [2]. The Saxenda pediatric trial still recorded depression in 4% of liraglutide patients versus 2.4% on placebo [1].

Children and teenagers

Saxenda is approved from age 12 for weight management in patients above 60 kg with obesity; Victoza from age 10 for type 2 diabetes [1][2]. Among SSRIs, the Zoloft label says safety and effectiveness in pediatric patients other than those with obsessive-compulsive disorder have not been established [3], while escitalopram is approved for major depression from age 12 and generalized anxiety from age 7 [5]. The Saxenda adolescent trial recorded one suicide in the liraglutide group that the investigator judged unlikely related to treatment [7].

Dosing from the labels

• Saxenda is injected once daily at any time of day, without regard to meals, and no dose adjustment is needed for changing injection site or timing [1].
• Saxenda titration runs 0.6 mg daily for week 1, then 1.2, 1.8 and 2.4 mg, reaching 3 mg daily at week 5. For adults, the label says to discontinue treatment if 3 mg daily is not tolerated. For pediatric patients, it allows a reduction to 2.4 mg daily [1].
• Victoza starts at 0.6 mg daily for one week, then increases to 1.2 mg daily. Its label allows an increase to 1.8 mg daily if more blood sugar control is needed after at least one week at 1.2 mg [2].